Definium's LSD Compound Just Posted Its Second Positive Phase 3 Trial for Anxiety
Panorama, Definium's second Phase 3 trial of DT120 (lysergide) for generalized anxiety disorder, met its primary endpoint on Sept 14 — a statistically significant and clinically meaningful improvement over placebo on the Hamilton Anxiety Rating Scale, across 245 participants. That's two-for-two: Panorama follows Voyage, DT120's first Phase 3 GAD trial, which also hit its primary endpoint back in August — full history on our Trials Tracker. Two independent positive Phase 3 readouts for the same drug and indication is a meaningfully stronger position than one — it's the kind of replication regulators specifically look for, and part of why Definium is currently the most valuable public psychedelic-adjacent company by market cap. DT120 still isn't FDA-approved for anything; an NDA filing hasn't been announced yet.
Read at Definium Therapeutics